1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Overview
1.1 Product Overview and Scope of Targeted Drug EGFR RTK Inhibitors for NSCLC
1.2 Classification of Targeted Drug EGFR RTK Inhibitors for NSCLC by Types
1.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Comparison by Types (2020-2025)
1.2.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Types in 2018
1.2.3 Icotinib
1.2.4 Gefitinib
1.2.5 Erlotinib
1.2.6 Afatinib
1.2.7 Osimertinib
1.2.8 Brigatinib
1.2.9 Other
1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market by Application
1.3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market by Regions
1.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug EGFR RTK Inhibitors for NSCLC Status and Prospect (2015-2025)
1.5 Global Market Size of Targeted Drug EGFR RTK Inhibitors for NSCLC (2015-2025)
2 Manufacturers Profiles
2.1 Beta Pharma
2.1.1 Business Overview
2.1.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.2 AstraZeneca
2.2.1 Business Overview
2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.3 Natco Pharma
2.3.1 Business Overview
2.3.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.4 Qilu Pharmaceutical
2.4.1 Business Overview
2.4.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.5 Genentech (Roche Group)
2.5.1 Business Overview
2.5.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.6 Mylan
2.6.1 Business Overview
2.6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.7 Teva
2.7.1 Business Overview
2.7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.8 OSI Pharmaceuticals
2.8.1 Business Overview
2.8.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.9 Glenmark Pharmaceuticals
2.9.1 Business Overview
2.9.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.10 Beacon Pharmaceuticals
2.10.1 Business Overview
2.10.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.11 Boehringer Ingelheim
2.11.1 Business Overview
2.11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.12 Pfizer
2.12.1 Business Overview
2.12.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.13 ARIAD Pharmaceuticals (Takeda)
2.13.1 Business Overview
2.13.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.14 Genvio Pharma Limited
2.14.1 Business Overview
2.14.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.15 Drug International Limted
2.15.1 Business Overview
2.15.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.16 Everest Pharmaceuticals
2.16.1 Business Overview
2.16.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.17 Incepta Pharmaceuticals Limited
2.17.1 Business Overview
2.17.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.18 Cipla Pharma
2.18.1 Business Overview
2.18.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.19 Dr Reddy\'s Laboratories
2.19.1 Business Overview
2.19.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Dr Reddy\'s Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.20 Zydus Cadila
2.20.1 Business Overview
2.20.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.21 Hetero Drugs
2.21.1 Business Overview
2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.22 Intas Pharmaceuticals
2.22.1 Business Overview
2.22.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.23 Alkem Laboratories
2.23.1 Business Overview
2.23.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.24 RPG Life Sciences
2.24.1 Business Overview
2.24.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
2.25 Fresenius Kabi India
2.25.1 Business Overview
2.25.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2019)
3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Competition, by Players
3.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drug EGFR RTK Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug EGFR RTK Inhibitors for NSCLC Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions
4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Market Share by Regions
4.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.5 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries
5.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2015-2019)
5.2 USA Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5.3 Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
5.4 Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries
6.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2015-2019)
6.2 Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.3 UK Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.4 France Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.5 Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
6.6 Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries
7.1 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2015-2019)
7.2 China Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.4 Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.5 India Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries
8.1 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2015-2019)
8.2 Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8.3 Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
8.4 Colombia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue Targeted Drug EGFR RTK Inhibitors for NSCLC by Countries
9.1 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Countries (2015-2019)
9.2 Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.3 UAE Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.4 Egypt Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.5 Nigeria Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
9.6 South Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Growth Rate (2015-2019)
10 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segment by Type
10.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue and Market Share by Type (2015-2019)
10.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Type (2020-2025)
10.3 Icotinib Revenue Growth Rate (2015-2025)
10.4 Gefitinib Revenue Growth Rate (2015-2025)
10.5 Erlotinib Revenue Growth Rate (2015-2025)
10.6 Afatinib Revenue Growth Rate (2015-2025)
10.7 Osimertinib Revenue Growth Rate (2015-2025)
10.8 Brigatinib Revenue Growth Rate (2015-2025)
10.9 Other Revenue Growth Rate (2015-2025)
11 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segment by Application
11.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Application (2015-2019)
11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Application (2020-2025)
11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2015-2019)
11.4 Adenocarcinoma of NSCLC Revenue Growth (2015-2019)
11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2015-2019)
12 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast (2020-2025)
12.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast (2020-2025)
12.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Regions (2020-2025)
12.3 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.6 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
